Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00310258 · ClinicalTrials.gov registry record · Phase 3
Drug Use Prevention Among Girls Through a Mother-Daughter Intervention
A Phase 3 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 3
- Development phase
- 2,000
- Enrollment target
NCT00310258: Completed Phase 3 study, sponsored by National Institute on Drug Abuse (NIDA).
NCT00310258 is a Phase 3 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 2,000 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (159% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00310258, a Phase 3 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,000 participants
- Enrollment target
Study Summary
This study will develop and test drug use prevention strategies for low-income, minority girls. Gender-specific substance use rates, risk and protective factors, and health outcomes highlight the need for interventions aimed at girls. Girls and boys share a number of risk factors, yet some factors are more salient for one gender. Girls and boys may also be affected differently by the same risk factors. Intervention planned for this study emphasizes risk and protective factors that impact girls. Our intervention will build mother-daughter communication and closeness; enhance girls' self-efficacy and body esteem; nurture girls' conflict management, problem-solving, stress reduction, and refusal skills; correct perceived norms; build social supports; and establish patterns of parental monitoring and supervision. We hypothesise that girls who receive GSI will have lower 3-year follow-up rates of substance use than girls who receive no intervention. The study will occur in three phases. In a 12-month preparation phase, we will refine and complete intervention and measurement protocols, recruit subjects and randomly assign girls and mothers to study arms, and pretest girls and mothers. A 12-month implementation phase will initiate field operations of the clinical trial, including intervention delivery, process data collection, and posttests. Follow-up in the last 36 months will involve longitudinal measurements of girls and mothers, booster session development and delivery, and data analyses.
Interventions
- BEHAVIORAL Drug use prevention intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2005-04 |
| Est. Completion | 2006-02 |
| Phase | Phase 3 |
What the finished NCT00310258 record still lists
NCT00310258 is an interventional study that assigns participants to a tested intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (159% higher).
The record links to 0 conditions, and to 1 intervention - of which Drug use prevention intervention is the first listed.
NCT00310258 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00310258 about?
NCT00310258 is a clinical study titled "Drug Use Prevention Among Girls Through a Mother-Daughter Intervention". This study will develop and test drug use prevention strategies for low-income, minority girls. Gender-specific substance use rates, risk and protective factors, and health outcomes highlight the need for interventions aimed at girls. Girls and boys share a number of risk factors, yet some factors a...
What is the current status of trial NCT00310258?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,000 participants. The study started on 2005-04. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00310258?
The interventions under investigation include: Drug use prevention intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT00310258?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00310258's enrollment target sits among peer trials
2,000 100th of 2000 higher than 1,895 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia